Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

STAAR Surgical Company

STAA ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Small Cap Analyst: HOLD

Last Close

$21.50

▼ -2.32%

Market Cap $1.08B · Vol 189.45K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

322.58

FWD: 44.14

Market Cap

$1.08B

Small Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+117.01%

YoY

RSI (14)

62.35

Momentum

Beta

1.24

vs Market

52W High

$35.83

39.99% below

52W Low

$15.59

37.91% above

Volume

189.45K

Avg 424.12K

P/B

3.39

Price-to-book

ROE

N/A

Return on equity

Free Float

99.15%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, STAAR Surgical Company (STAA) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does STAA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.93%

-5.12%

-22.61%

-19.90%

YTD

-6.89%

-21.10%

-46.80%

-81.39%

Financials & Valuation

TTM · Annual

Total Revenue	$239.44M
Net Income	$-80,448,000.00
Revenue Growth (YoY)	+111.04%
Gross Margin	76.19%
Operating Margin	-19.16%
Net Profit Margin	-33.60%
ROE	N/A
ROA · ROIC	-17.12% · N/A

P/E Ratio	322.58
Forward P/E (FY1)	44.14
PEG Ratio	N/A
P/S	4.89
P/B	3.39
P/FCF	N/A
EPS Growth	+117.01%
Outstanding Shares	50.14M

Technical Indicators

50-Day SMA	$22.81
200-Day SMA	$23.59
RSI (14)	62.35
Beta	1.24
52-Week High	$35.83
52-Week Low	$15.59

Volume Today	189.45K
Avg Daily Volume (30D)	424.12K
Relative Volume	0.45x
Volatility (10D)	23.97
Volatility (30D)	46.84
Free Float	99.15%

Analyst Consensus

HOLD

Current Price $21.50

Mean Target $28.00

52W Low$15.59 52W High$35.83

Current

Target

$15.59 $35.83

Current Analyst target

+30.23% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S6MC39

ISINUS8523123052

CountryUSA

Sub-IndustryMedical Equipment, Supplies & Distribution (NEC)

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeUNT Unit

Similar Halal Stocks

ABT Abbott Laboratories +0.78% MDT Medtronic PLC +1.17% COR Cencora, Inc. +1.55% 7741.T HOYA CORPORATION +1.04% BDX Becton Dickinson and Co -0.80%

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also markets and sells an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company's principal products are ICLs used in refractive surgery, including its EVO family of lenses.